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Abstract: Infusions of Orthosiphon stamineus Benth., Lamiaceae, leaves are widely 
used in Southeastern Asia to treat different illnesses. Nonetheless, no data is available 
on the safety of O. stamineus for pregnant women and their babies. This study was 
undertaken to evaluate the developmental toxicity of O. stamineus standardized 
aqueous extract in female Sprague Dawley rats (n=21) at 0, 250, 500, 1000 and 2000 
mg/kg/day, by gavage on gestation days 6-20. Clinical signs of maternal toxicity, 
body weight gain, and food and water consumption were recorded. Caesarean sections 
were performed on gestation day 21; resorptions and living and dead fetuses were 
counted. Fetuses were weighed and examined for external abnormalities. Half of 
the fetuses from each litter were cleared and stained with Alizarin red S for skeleton 
evaluation. O. stamineus standardized aqueous extract did not alter pregnancy body 
weight gain and food and water consumption and caused no other sign of maternal 
toxicity. Embryolethality and prenatal growth retardation were not observed either. O. 
stamineus standardized aqueous extract increased a few skeleton variations and a skull 
bone malformation (hyoid bone absent) in a non-dose dependent manner. Anogenital 
distance was increased in male and female fetuses exposed to the highest O. stamineus 
standardized aqueous extract dose, an indication that the extract could possibly contain 
androgenic compounds. 
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Introduction
 Orthosiphon stamineus Benth., Lamiaceae, 
or “Java tea” is a medicinal plant traditionally used in 
Southeastern Asia. It is also known as “MisaiKucing” in 
Malaysia, “Kumis Kucing” in Indonesia, “Balbas-pusa” 
and “Kabling-gubat” in Philippines, “Kapen prey” in 
Cambodia, “Hnwàdméew” in Laos, “YaaNuatMaeo” in 
Thailand, and “Thé de Java” in French speaking countries 
(Anon, 2001). In Southeastern Asia people are currently 
exposed to O. stamineus through the consumption of 
infusions made with its leaves, medicinal potions and 
phytotherapeutic drugs. In Malaysia, a tea made with O. 
stamineus leaves is used to improve health and to treat 
a variety of diseases such as kidney disorders, bladder 
infl ammation, gout, diabetes, eruptive fevers,  hepatitis, 
hypertension, syphilis, rheumatism and gonorrhoea 
(Akowuah et al., 2004; Ameer et al., 2012). 
 Studies on the pharmacological properties of O. 
stamineus extracts seem to lend support to some of their 
common uses in folk medicine. Anti-oxidant and anti-
infl ammatory activities as well as a benefi cial effect on 
hyperglycemia and altered lipid profi le in diabetic rats have 
been reported (Arafat et al., 2008). Diuretic properties of 
aqueous extracts of O. stamineus were demonstrated as 
well (Adam et al., 2009). Methanol (50%) extracts of O. 
stamineus, on the other hand, were described to have anti-
pyretic activity (Yam et al., 2009) and to inhibit the growth 
of food-borne bacteria (Vibrio parahaemolyticus) in vitro 
test systems (Ho et al., 2010).
 Methoxylated fl avones (sinensetin and eupatorin) 
and phenolic acids (rosmarinic and caffeic acids) were 
identifi ed in O. stamineus leaf extracts (Muhammad et al., 
2011; Ameer et al., 2012). It is of note that rosmarinic acid, 
a major component of aqueous extracts from O. stamineus 
leaves, has been reported to exhibit antioxidant, immuno-
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modulatory and anti-cancer activity (Scheckel et al., 2008; 
Yam et al., 2009; Ameer et al., 2012).
 Although being widely used in folk medicine, 
there is a paucity of toxicological data on O. stamineus 
extracts. A few previous studies suggested that O. 
stamineus extracts are of low acute toxicity and pose 
no genotoxic risk (Han et al., 2008; Abdullah et al., 
2009; Muhammad et al., 2011). The reproductive 
and developmental toxicity of O. stamineus extracts, 
however, have not been investigated so far. Along the 
same line, almost no information is available on the 
embryo/fetotoxic potential of major constituents of 
O. stamineus extracts such as caffeic acid, euptorin 
and sinensetin. Since O. stamineus extracts are often 
consumed by women of childbearing age, studies of 
their safety in pregnancy are of the utmost importance. 
 This study was undertaken to provide data on the 
developmental toxicity of O. stamineus aqueous extract in 
rats.
Materials and Methods
Plant material and extract preparation
 The standardized aqueous extract of Orthosiphon 
stamineus Benth., Lamiaceae (OSAE), was purchased 
from Nova Laboratories Sdn. Bhd (Malaysia). Dried plant 
aerial parts were ground to a homogeneous powder and left 
to stand in water at 70 oC for 30 min. The plant infusion 
was then filtered, evaporated and concentrated. The 
resulting concentrated liquid extract was spray-dried at 
180 oC (outlet temperature) and 100 oC (inlet temperature) 
producing a powder that (OSAE) was further used in the 
experiments. Extraction yield was 4.8%. OSAE major 
constituents were determined at the Phytochemistry Unit, 
Herbal Medicine Research Centre. High Performance 
Liquid Chromatography-Diode Array Detector (HPLC-
DAD) was used to analyze the OSAE. Quantification of 
rosmarinic acid, the major constituent of OSAE extract, 
was undertaken using the external standard method and its 
amount in the extract was calculated based on the peak 
area of the chromatogram with the calibration curve of the 
standard compound. Linear regression plots were obtained 
(waters Empower 2 software) and results were expressed 
as micrograms of rosmarinic acid per gram of OSAE. 
Qualitative and quantitative analyses were performed on 
Waters 2695 Alliance HPLC system (Waters, MA, USA). A 
C-18 column (Phenomenex, Luna 3μm, 100x4.6 mm.,i.d.) 
guarded by a C-18 security guard cartridges was used. 
Mobile phase was made of solvent A: water:trifluoracetic 
acid (TFA) (20:0.001;v/v) and solvent B: acetonitrile:TFA 
(20:0.001; v/v) and gradient elution was as follows: 0-2 
min, 30% B; 2-10 min, 30-50% B; 10-20 min, 50-95% B 
and finally washing the column with 95% B for 2 min and 
reconditioning it with 30% B isocratic for 2 min. Flow rate 
was 0.5 mL/min and injection volume was 10 μL. Peaks 
were analyzed at 340 nm.
Chemicals
 Glycerol, methanol, ammonium sulphide and 
potassium hydroxide were purchased from Merck, 
Chemical Germany. Acetic acid and 95% ethanol were 
from Hamburg. Diethyl ether was purchased from Fisher. 
Bouin’s solution and Alizarin Red S were from Sigma-
Aldrich, UK.
Animals
 Virgin females (n=105; 180-200 g) and fertile 
males (n=55; 200-250 g) Sprague-Dawley (SD) rats, 
supplied by the Animal Resource Unit (Medical Resource 
Centre, Institute for Medical Research, Malaysia) were 
used. Upon arrival at the lab, animals were housed in rat 
standard polypropylene cages, lined with wood shavings 
and kept at controlled temperature (20±2 oC), air relative 
humidity (40-60%) and photoperiod (12 h of light and 
12 h of dark cycle). All rats were acclimatized for one 
week prior to the start of the study. A commercial rat diet 
(Specialty Feeds, Australia) and water were available ad 
libitum. Approval for this study was obtained from the 
Animal Care and Ethics Committee, Ministry of Health 
Malaysia (ACUC No: ACUC/KKM/02 (2/2007).
Experimental design
 Female rats in the pro-oestrous phase (oestrous 
cycle phase was determined by vaginal smear cytology) 
were placed into the cage of males (on a one-to-one 
basis) in the late morning and removed in the following 
morning (24 h). The day on which overnight mating was 
confirmed by the presence of sperm in the vaginal smear 
was designated as gestation day 0 (GD0).
Treatment
 The OSAE (0, 250, 500, 1000 or 2000 mg/
kg/day), dissolved in distilled water, was administered 
(volume: 10 mL/kg) orally (gavage) to pregnant rats on 
GD 6-20. OSAE aqueous solutions were prepared daily. 
Once a day, after treatment, rats were observed in their 
cages for 60 min, and behavioural changes and clinical 
signs of toxicity were recorded. Maternal body weight 
(on a daily basis) and food and water intake (on a weekly 
basis) were measured and recorded. 
Caesarean section and fetal examination
 On GD21 rats were euthanized by ethyl ether 
inhalation and caesarean section was performed. The 
Study on the developmental toxicity of a standardized extract of Orthosiphon 
stamineus in rats 
Hussin Muhammad et al.
Rev. Bras. Farmacogn. Braz. J. Pharmacogn. 23(3): May/Jun. 2013 515
gravid uterus was removed and weighed with its contents. 
The number of corpora lutea graviditatis in both ovaries 
was then counted. Implantation sites were determined by 
the method of Salewski (1964). Resorptions and living and 
dead fetuses were counted. Placentas were examined and 
weighed. Fetuses were removed by cutting the umbilical 
cord close to their bodies, examined for externally visible 
abnormalities under a stereomicroscope, sexed, numbered, 
and fixed in Bouin’s solution. The anogenital distance 
(AGD) of all fetuses was measured using a digital caliper. 
Half of the fetuses of each litter, selected at random, were 
macerated in potassium hydroxide, cleared with glycerin-
KOH solutions and stained with Alizarin Red S for skeleton 
evaluation (Staples & Schnell, 1964). The remaining 
fetuses were examined for soft-tissue anomalies and their 
heads were serially sectioned with a razor blade. Maternal 
organs were examined for gross pathology abnormalities 
and liver, kidneys, lungs and heart were removed and 
weighed. 
Statistical analysis
 Data on maternal body weight, weight gain 
during pregnancy, food and water consumption, fetal body 
weight, placenta weight, maternal organ weights (absolute 
and relative weights) were analysed by one-way analysis 
of variance (ANOVA) and Dunnett’s post hoc test. Number 
(per litter) of corpora lutea graviditatis, implantations, 
live and dead fetuses, and resorptions were evaluated by 
the Kruskal-Wallis test followed by the Mann-Whitney 
U test. Proportions of fetuses and litters showing a given 
abnormality were compared by the chi-square. In any 
case, a difference was significant when p<0.05. Statistical 
analyses were performed using SPSS version 16.
Results
Extract major constituents
 HPLC analysis identified two phenolic acids, 
caffeic acid and rosmarinic acid, and two methoxylated 
flavones, sinensetin and eupatorin, in the OSAE. The 
foregoing markers found in the OSAE are consistent with 
those reported in the literature for O. stamineus extracts. 
The amount of rosmarinic acid, the major constituent of 
OSAE, was 44.00±1.88 μg of rosmarinic acid per mg of 
OSAE (4.40% w/w).
Pregnancy weight gain and signs of maternal toxicity
 All control and treated dams survived to 
scheduled euthanasia. At the necropsy, no gross 
pathology alterations were found in OSAE treated 
females. Pregnancy weight gains - either with or 
without subtracting gravid uteri weights - were not 
altered at any dose level of OSAE (Table 1). Weight of 
Table 1. Maternal weight gain of rats treated orally with Orthosiphon stamineus aqueous extract (0, 250, 500, 1000 and 2000 mg/kg/
day) on days 6-20 of gestation.
O. stamineus aqueous extract (mg of dried extract/kg/day)
0 250 500 1000 2000
Treated females (n) 21 21 21 21 21
Pregnant females (n) 21 21 21 21 21
Pregnant/treated females (%) 100 100 100 100 100
Maternal weight (g)
GD0 197.2±15.0 196.6±15.6 195.4±12.3 196.7±11.6 191.6±9.3
GD21 352.6±21.0 355.0±35.0 345.4±30.4 354.1± 31.6 349.2±29.4
Gravid uterus weight (g) 85.6±11.9 90.0±15.9 89.6±12.5 84.9±19.7 85.2±17.4
Maternal weight gain (Δ g)
GD0-6 34.5±7.2 31.8±10.8 32.5±8.7 35.40±09.77 33.82±05.58
GD6-9 13.5±5.3 14.6±7.89 12.6±5.4 13.22±05.63 13.93±05.11
GD9-12 17.3±8.5 17.0±6.3 14.4±8.2 15.63±06.94 17.00±07.33
GD12-15 16.3±8.4 15.9±11.2 15.8 ±9.3 19.8±10.2 16.8± 6.6
GD15-18 30.9±8.1 33.0±8.3 33.1±4.0 32.8±6.9 33.2±07.0
GD18-21 43.2±9.0 43.7±13.1 41.5±7.5 42.8± 7.8 43.0±11.8
GD0-21 155.4±15.3 158.0±32.3 150.0±29.7 157.4±29.2 157.6±26.2
GD0-21 69.8±17.1 67.9±24.2 60.4±20.4 72.4± 18.7 72.5 ±14.2
(minus gravid uterus weight)
Data shown as means±SD were analyzed by ANOVA and no difference (p>0.05) among dose groups was found.
Study on the developmental toxicity of a standardized extract of Orthosiphon 
stamineus in rats 
Hussin Muhammad et al.
Rev. Bras. Farmacogn. Braz. J. Pharmacogn. 23(3): May/Jun. 2013516
and OSAE treated groups. Taken together, data on the 
resorption rate and mean number of live fetuses at term 
consistently showed that OSAE, given to dams in doses 
up to 2000 mg/kg/day on GD6-20, did not cause any 
increase of post-implantation losses over the incidence 
recorded in the control group. The mean number of 
males and females per litter also remained unaltered in 
control and OSAE treated groups.  
Effects on placenta, fetal body weight and anogenital 
distance 
 The mean weight of placentas in OSAE-treated 
groups was comparable to that of the control group 
(Table 2). The mean fetal body weight in OSAE treated 
groups did not differ from that in the control group either. 
The anogenital distance (AGD) index, however, was 
significantly increased (p<0.05) over control AGD index 
measurements in male as well as in female offspring of 
dams treated with 2000 mg of OSAE/kg/day. Since AGD 
may vary with fetal body weight (Gallavan et al., 1999), 
AGD was normalized to body weight using the cube 
root of the body weight (AGD/body weight⅓). The same 
conclusion about the effect of OSAE on AGD was reached 
when statistical comparisons were made using direct 
measurements of AGD (not shown).  
maternal organs (liver, kidneys, heart and lungs) did not 
differ between OSAE-treated and control rats (data not 
shown). Mild diarrhoea and softer faeces were noted in 
dams that received OSAE, i.e., in 1, 2, 3 and 1 dams from 
groups treated with 250, 500, 1000 and 2000 mg/kg/day, 
respectively. No behavioural alterations and no other 
clinical signs of toxicity were observed among treated 
dams. Food and water intakes of treated and control 
group dams were similar throughout pregnancy (data not 
shown). 
Effects on the incidence of embryo-fetal death
 
 Pregnancy was confirmed for all sperm positive 
females, i.e., all control and treated dams presented 
implantation sites in their uteri. The data obtained 
at the caesarean section are shown in Table 2. Mean 
numbers of corpora lutea graviditatis and implantation 
sites per litter did not differ between OSAE-treated and 
control groups. The foregoing findings indicated that 
exposure to OSAE from GD6 onwards did not induce 
peri-implantation losses. The occurrence of early and 
late resorptions was low in control and treated groups 
and the percentage of resorptions per litter (median) 
was not altered by OSAE administration. The average 
number of live fetuses per litter was similar in control 
Table 2. Caesarean section data of rats treated orally with O. stamineus aqueous extract (0, 250, 500, 1000 and 2000 mg/kg /day) on 
days 6-20 of gestation.
O. stamineus aqueous extract (mg of dried extract/kg/day)
0 250 500 1000 2000
Corpora lutea (per litter, n) 13.0 (2.5) 14.0 (3.5) 14.0 (3.0) 13.0 (2.5) 14.0 (3.0)
Implantations:
    Total (n) 265 273 275 272 264
    Per litter (n)a 12.6±1.9 13.0±2.3 13.1±1.9 13.0±1.9 12.6±2.5
Resorptions
    Total (n) 19 11 9 32 17
    Per litter (n) bEarly 1 (1) 0 (1) 0 (1) 1 (2) 1 (1)
    Late 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Resorptions per litter (%) b 6.7 (9.2) 0 (8.4) 0 (6.7) 6.7 (22.5) 6.7 (11.2)
Live fetuses per litter (n) a 11.7±2.0 12.5±2.5 12.7±1.8 11.4±3.0 11.7±2.5
    males per litter (n) a 6.4±2.0 6.0±2.2 6.6±2.2 5.7±2.3 5.8±2.1
    females per litter (n) a 5.3±2.0 6.4±1.4 6.0±1.9 5.5±2.4 6.0±2.6
Fetal body weight (litter, g) a 5.47±0.32 5.45±0.34 5.30±0.28 5.55±0.40 5.46±0.33
Placenta weight (g) a 0.56±0.15 0.51±0.05 0.49±0.05 0.53±0.17 0.53±0.08
Anogenital (AGD) distance (litter) index#
    males a 1.38±0.11 1.45±0.10 1.41±0.11 1.42±0.07 1.47±0.11*
    females a 0.48±0.06 0.51±0.06 0.51±0.06 0.50±0.05 0.55±0.06*
aData shown as means±SD were analyzed by ANOVA and Dunnett’s post hoc test and differences (p<0.05) are indicated by an asterisk (*). bData 
shown as median and interquartile range (IQR) were analyzed by the Kruskal-Wallis test and no difference (p>0.05) among groups was detected.# 
AGD Index: AGD mm/cube root of body weight.
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Effects on the occurrence of structural anomalies
 OSAE administered on GD6-20 did not cause 
externally visible anomalies in the offspring of treated 
dams. Similarly, examination of fixed fetuses for soft 
tissue anomalies, including serial sections of brain, did not 
reveal any malformation (data not shown). The skeleton 
abnormalities found in control and OSAE-treated fetuses 
are shown in Table 3. The main OSAE treatment-related 
skeletal abnormalities were incomplete ossification of 
some skull bones (os parietale, os occipitale and os hyoid), 
sternebra 1, and a forelimb long bone (os humerus), and a 
poor ossification of forelimb digits. Incidences of additional 
ossification site in os interparietale and dumbbell shaped 
thoracic vertebra centra were slightly enhanced as well. 
Although being statistically significant at one or more 
OSAE treated groups, enhanced occurrences of foregoing 
skeleton abnormalities were not dose dependent. The 
aforementioned skeleton abnormalities are generally 
classified as variations (Solecki et al., 2001). An increased 
incidence of absent hyoid bones was noted in fetuses from 
dams treated with the lowest dose of OSAE (250 mg/kg 
body weight/day). Missing bones are a generally considered 
as typical malformations and thus should be classified the 
absence of hyoid bone (Gallavan et al., 1999). 
Discussion
 Results from this study showed that, except 
for mild diarrhoea, OSAE administered orally to 
dams in doses up to 2000 mg/kg/day on GD6-20 did 
not cause overt maternal toxicity. The mild diarrheic 
symptoms noted in some rats treated with OSAE were 
not accompanied by reductions of body weight gain or 
alterations of food and water intakes and thus they were 
interpretedas being of minor toxicological significance. 
The absence of signs of maternal toxicity in this study 
was consistent with previous reports that O.stamineus 
extracts and their major constituent (rosmarinic acid) 
present low acute and subacute toxicities (Abdullah 
et al., 2009; Yam et al., 2009). The oral LD50 of O. 
stamineus methanol extract in rats, for instance, was 
higher than 5000 mg/kg (Yam et al., 2009).
 The fact that resorption rates (resorptions per 
litter) and litter sizes (number of live fetuses per litter) 
at term remained unaltered indicated that OSAE, did not 
cause embryo and fetal deaths. Likewise, unchanged ratios 
of treated (sperm positive) per pregnant females (i.e., with 
detected implantations sites) and numbers of corpora lutea 
graviditatis per litter suggested that OSAE did not cause 
peri-implantation losses either. Results, therefore, indicated 
that OSAE did not induce peri- or post-implantation 
gestational losses. 
 The absence of effects on placenta and fetal 
body weights showed that OSAE administered to dams 
throughout embryogenesis (GD6-15) and fetal maturation 
(GD15-20) periods did not retard prenatal growth of 
exposed offspring. Furthermore, results from this study 
provided no evidence that administration of OSAE 
enhanced the incidence of externally visible and soft tissue 
anomalies in the exposed fetuses. 
 Skeletal abnormalities observed in OSAE-
exposed fetuses, such as incomplete ossification of os 
parietale, os hyoid, sternebra 1 and os humerus, poor 
ossification of forelimb digits and dumbbell shaped 
thoracic vertebra centra, are generally classified as 
variations (Gallavan et al., 1999). Additional ossification 
in os interparietale occurs at a high background incidence 
in rats from our breeding stock (e.g., 8.8 % of fetuses 
and 23.8% of litters in the control group) and should also 
be considered as a variation. The absence of os hyoid, 
on the other hand, is to be classified as a malformation. 
It should be borne in mind, however, that increased 
occurrences of the aforementioned skeletal variations 
and hyoid bone absence in OSAE exposed fetuses were 
not dose dependent effects. Owing to their low severity 
and or to the fact that observations were non-dose-related 
the foregoing skeletal abnormalities were not taken into 
account for setting the study-derived no- observed-
adverse- effect-level (NOAEL) for OSAE.
 A longer AGD in male and female offspring from 
mothers treated with the highest dose (2000 mg/kg/day) 
was the main developmental toxic effect of OSAE found 
in this study. AGD is a sexually dimorphic measure of 
genital development and a sensitive marker for endocrine 
disruption in rodent studies. Testosterone secretion by 
fetal testis increases the AGD in males relative to the 
distance in females at term. The AGD is also influenced by 
intrauterine position of the conceptus, being a longer AGD 
associated with the presence of males on either side of the 
developing female fetus, and a shorter AGD associated 
with absence of males on either side of the developing 
female fetus (vom Saal et al., 1983; Hotchkiss et al., 
2007; Han et al., 2008). Pre-natal exposure to hormonally-
active compounds has also been shown to alter AGD. For 
instance, in utero (GD14-19) exposure of Sprague Dawley 
rats to the potent androgenic compound trenbolone was 
found to increase neonatal AGD, to delay puberty and to 
masculinize female offspring behavior (Han et al., 2008). 
The mode by which OSAE, at the highest dose tested, 
increased AGD in both male and female fetuses remains 
obscure. The presence of androgenic compounds in the 
extract is a plausible explanation for this effect and should 
be further investigated.
 Data provided by this study showed that OSAE, 
tested in oral doses up to 2000 mg/kg/day given to Sprague 
Dawley rats on GD6-20, was not maternally toxic nor did it 
caused embryofetal deaths, prenatal growth retardation or 
structural malformations in the exposed offspring. Longer 
AGD in male and female fetuses at the highest dose tested 
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Treatment
O. stamineus aqueous extract (mg of dried extract/kg/day)
0 250 500 1000 2000
Fetuses (litters) examined (n): 125 (21) 128 (21) 127 (21) 112 (21) 118 (21)
Percentage of fetuses showing anomalies (%) in:
Skull
Os. parietale (incpl.ossif.) 1.6 (9.5) 9.4* (33.3) 2.4 (14.3) 5.4 (23.8) 9.3* (38.1)
Os. frontale (incpl.ossif.) 0.8 (4.8) 0.8 (4.8) 1.6 (4.8) 0.9 (4.8) 1.7 (9.5)
Os. occipitale (incpl.ossif.) 0 (0) 4.7* (19)* 3.9 (14.3) 1.8 (9.5) 0 (0)
Os. interparietale (ad.ossif.)     8.8 (23.8) 25.8* (71.4)* 14.2 (57.1)* 24.1* (85.7)* 30.5* (76.2)*
Os. supraoccipitale (misshap.) 0 (0) 0 (0) 0 (0) 0.9 (4.8) 0 (0)
Os hyoid (absent) 0 (0) 9.4* (33.3)* 3.2 (19) 3.6 (9.5) 2.5 (9.5)
               (incpl.ossif) 1.6 (9.5) 3.1 (14.3) 7.9 (42.9)* 3.6 (19) 1.7 (9.5)
Proc. jugalis maxila (incpl.ossif) 0 (0) 1.6 (9.5) 1.6 (4.8) 0.9 (4.8) 2.5 (14.3)
Os. zygomatic (incpl.ossif) 0 (0) 2.3 (14.3) 0.8 (4.8) 0 (0) 0.8 (4.8)
Sternum
 All stenerbrae (split) 0.8 (4.8) 0 (0) 0 (0) 0 (0) 0 (0)
                        (misaligned) 5.6 (23.8) 0.8 (4.8) 2.4 (9.5) 0* (0) 5.9 (19)
Sternebra 1 (split) 0 (0) 0 (0) 0.8 (4.8) 0 (0) 0 (0)
                   (incpl.ossif.) 0.8 (4.8) 6.2 (19) 1.6 (9.5) 6.2 (19) 8.5* (33.3)*
Sternebra 2 (misshap.) 0 (0) 0.8 (4.8) 0.8 (4.8) 0 (0) 0.8 (4.8)
                   (smaller) 0 (0) 0 (0) 0.79 (4.8) 0.9 (4.8) 1.7 (9.5)
                   (incpl.ossif.) 1.6 (9.5) 0.8 (4.8) 2.36 (14.3) 0 (0) 0.8 (4.8)
Sternebra 4 (misshap.) 0.8 (4.8) 0 (0) 0 (0) 0 (0) 0 (0)
                   (incpl.ossif.) 1.6 (9.5) 0 (0) 0 (0) 0 (0) 0 (0)
Sternebra 5 (misshap.) 15.2 (38.1) 19.5 (66.7) 3.9* (23.8) 13.4 (52.4) 21.2 (71.4)
                   (smaller) 10.4 (33.3) 10.9 (33.3) 3.2 (19) 15.2 (57.1) 17.0 (47.6)
                   (incpl.ossif.) 1.6 (9.5) 0 (0) 0 (0) 0 (0) 0 (0)
                   (absent) 0.8 (4.8) 1.6 (9.5) 0 (0) 0 (0) 0.8 (4.8)
Xiphisternum (split) 0 (0) 0 (0) 0.8 (4.8) 0 (0) 0 (0)
                       (incpl.ossif.) 3.2 (19) 1.6 (9.5) 0 (0) 1.8 (9.5) 0.8 (4.8)
Ribs
         (fused) 0 (0) 0.8 (4.8) 0 (0) 0 (0) 0 (0)
         (wavy) 0.8 (4.8) 1.6 (4.8) 1.6 (9.5) 0.9 (4.8) 0.8 (4.8)
         13th rib (short) 0.8 (4.8) 3.1 (14.3) 3.2 (19) 1.8 (9.5) 0 (0)
Supernumery rib (short)
          (both sides) 0 (0) 0 (0) 0.8 (4.8) 0 (0) 1.7 (4.8)
          (one side) 0 (0) 0 (0) 2.4 (14.3) 1.8 (9.5) 1.7 (9.5)
           14th Rib (rudimentary)
                        (both sides) 4 (23.8) 3.9 (14.3) 3.9 (19) 2.7 (9.5) 6.8 (28.6)
                        (one side) 6.4 (23.8) 6.2 (28.6) 5.5 (28.6) 2.7 (14.3) 7.6 (38.1)
Vertebral column
Atlas (misshap) 0 (0) 0 (0) 0 (0) 0.9 (4.8) 0 (0)
          (incpl.ossif) 0 (0) 0.8 (4.8) 0 (0) 3.6 (14.3) 0 (0)
Thoracic verto.c. (dumbbell) 4.0 (9.5) 7.0 (28.6) 7.1 (42.9)* 8.9 (28.6) 3.4 (19)
                            (bipartite) 0.8 (4.8) 3.1 (9.5) 0.8 (4.8) 0.9 (4.8) 0.8 (4.8)
                         (hemicentric) 0 (0) 1.6 (4.8) 0 (0) 0 (0) 0 (0)
Lumbar vert o.c.  (dumbbell) 0.8 (4.8) 0 (0) 0 (0) 0 (0) 0 (0)
Table 3. Occurrence of skeletal abnormalities in the offspring of SD rat treated orally with O. stamineus aqueous extract (0, 250, 500, 
1000 and 2000 mg/kg/day) on days 6-20 of gestation.
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as compared to that in control fetuses of the same gender 
was the most conspicuous developmental adverse effect 
of OSAE found in this study. The study-derived no-
observed-adverse effect levels (NOAEL) for maternal and 
developmental toxicities were set at >2000 and 1000 mg 
of OSAE per kg body weight per day by the oral route, 
respectively. Taken into account that extraction yield was 
4.8%, the foregoing NOAEL corresponds to 96 and 48 g of 
dried leaves of O. stamineus per kg body weight per day, 
respectively. It is of note that the study-derived NOAEL 
for developmental toxicity is far in excess of the estimated 
amount of O. stamineus currently consumed by women of 
childbearing age through the use of teas, medicinal potions 
and phytotherapeutic drugs.
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